China Releases New Regs To Step Up Quality Control For Essential Drugs; Second Part Of EDL Expected In November
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - In the latest effort to strengthen drug safety measures in China, China's State FDA issued Sept. 24 a new quality control regulation for drugs listed on the Essential Drug List. The regulation asks local FDAs to conduct at least two inspections every year of all manufacturing sites for drugs listed
You may also be interested in...
Facing Pricing Pressure And Generic Erosion, Simcere Shifts To Innovative Products For Future Growth: China Earnings Roundup (Part I)
China’s healthcare industry saw slower growth in the third quarter. In a recurring feature, PharmAsia News combs through earnings reports to bring you highlights of China’s leading pharma companies and how their efforts affect different sectors of the industry.
China State FDA Reforms Expected, But When?
China's State FDA insists it will align the country's pharmaceutical and medical device regulations with international standards. The question on manufacturers' minds is, how soon
China State FDA Reforms Expected, But When?
China's State FDA insists it will align the country's pharmaceutical and medical device regulations with international standards. The question on manufacturers' minds is, how soon